Semax Peptide
Benefits
Originally used in stroke and brain injury patients, Semax has been studied in both clinical and real-world settings for a wide range of benefits:
Enhanced Focus and Attention
Semax is particularly effective for individuals with ADHD symptoms, brain fog, or concentration difficulties. It helps sustain attention and executive function without the crash associated with stimulants.
Improved Memory and Learning
Studies show Semax enhances both short-term and long-term memory recall, especially under high cognitive demand.
Mood Stabilization
By modulating dopamine and serotonin, Semax supports emotional resilience and reduces symptoms of mild to moderate depression.
Neuroplasticity and Recovery
Semax accelerates neural regeneration and has been shown to help patients recover faster from traumatic brain injury, stroke, or chronic stress.
Motivation and Energy
Many users report a noticeable boost in motivation, productivity, and mental stamina, especially when alternating with Selank.
Semax Synergy
While Semax is powerful on its own, the best results occur when combined with functional medicine strategies that reduce neuroinflammation and support brain biochemistry.
Semax is often combined with:
- Omega 1300 – high-dose EPA for brain membrane support
- CoQ10 Omega – mitochondrial support for mental stamina
- B12 & Folate – for methylation, neurotransmitter synthesis
- PineBark-400 – reduces neuroinflammation
- Selank peptide – paired to balance Semax’s stimulating effects with emotional calming
Dosage
The initial dosage will be higher to boost recovery and once cognitive capacity has been stabilized a lower continued ongoing dose can be employed.
Recovery Dose:
– 1000-1500mcgs (20-30ius on the insulin syringe) daily for week 1.
– 500-1000mcgs (10-20ius) daily for week 2.
Maintenance Dose:
– 250-500mcgs (5-10ius) daily week 3.
– Weeks 4-8 – 250-500mcgs (5-10ius) Mon-Wed-Fri or as needed. Some experimentation will be required to optimize the protocol.
Cycle:
Total on-cycle time 6-8 weeks, with a 6-8 week off-cycle period.
References
- Ashmarin, I. P., et al. (1998). Semax: A novel peptide with anxiolytic and nootropic properties. Neuroscience and Behavioral Physiology, 28(6), 713–718.
- Volkov, A. A., et al. (2016). Semax-induced changes in gene expression and BDNF signaling in rat brain. Molecular Biology Reports, 43(9), 945–954.
- Myasoedov, N. F., et al. (2000). The effects of Semax on learning and memory in animal models. Bulletin of Experimental Biology and Medicine, 130(2), 102–105.
- Glazova, M. V., et al. (2003). Antidepressant and anxiolytic properties of the peptide Semax. Neuroscience and Behavioral Physiology, 33(4), 377–381.
- Miasoedov, N. F. (2008). Neuropeptides in the regulation of higher nervous activity. Neurochemical Journal, 2(1), 17–23.
